Compare McKesson Corporation (MCK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Tesla, Inc. — how do they compare? McKesson Corporation trades at $824.07 (market cap $97.35B), while Tesla, Inc. trades at $381.06 (market cap $1.39T). The key difference: Tesla, Inc. is far larger — about 14.3× McKesson Corporation's market cap, and McKesson Corporation pays a 0.39% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| MCK | TSLA | |
|---|---|---|
Market Cap | $97.35B | $1.39T |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $489.88 |
52-Week Low | $659.01 | $302.63 |
Enterprise Value | $101.98B | $1.36T |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Tesla trades at $381.64, up 0.21% on the day, amid a bearish technical signal and mixed earnings history. The stock faces valuation concerns with a P/E of 339.06 and P/S of 13.34, while profitability metrics like net income margin have declined to 3.95% in 2025. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, but delivery misses and competitive pressures weigh on sentiment.
Tesla's outlook balances innovation in autonomy and energy against slowing auto growth and high valuations. Investment opportunities lie in AI and robotics expansion, but risks include execution challenges, intense EV competition, and reliance on future technology adoption. Analyst consensus is mixed with a $409.26 price target, suggesting cautious optimism amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
